Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Champion Homes, Inc.
SKY·Consumer Discretionary
B ★★★Hold
Current$93.16
Target$102.00
Return+9.5%
Nov 6, 2026

Champion Homes offers a financially resilient way to participate in long-term affordable-housing demand, but persistent manufacturing margin pressure and a demanding valuation limit near-term upside.

Score
69
Revvity, Inc.
RVTY·Healthcare
B ★★★Hold
Current$150.83
Target$152.50
Return+1.1%
Nov 6, 2026

Revvity's specialized life-sciences and diagnostics franchises offer improving organic growth and strong cash generation, but elevated valuation multiples and weak reported returns on capital limit near-term upside.

Score
69
Coca-Cola Europacific Partners PLC
CCEP·Consumer Staples
B ★★★Hold
Current$117.29
Target$113.00
Return-3.7%
Nov 6, 2026

Coca-Cola Europacific Partners combines a durable beverage distribution moat, resilient cash flow and disciplined shareholder returns, but elevated valuation and substantial leverage limit near-term upside.

Score
69
UL Solutions Inc.
ULS·Industrials
B ★★★Hold
Current$76.15
Target$84.80
Return+11.4%
Nov 6, 2026

UL Solutions combines a durable certification franchise, high capital returns and expanding testing demand, but its substantial peer valuation premium and acquisition integration requirements constrain near-term upside.

Score
69
International Flavors & Fragrances Inc.
IFF·Materials
B ★★★Hold
Current$86.36
Target$94.32
Return+9.2%
Nov 6, 2026

IFF's specialty ingredient franchise and major portfolio divestitures could unlock stronger margins, cash flow, and shareholder returns, but weak historical capital efficiency and execution risks limit the near-term margin of safety.

Score
69
Rio Tinto Group
RIO·Materials
B ★★★Hold
Current$84.56
Target$90.20
Return+6.7%
Nov 5, 2026

Rio Tinto combines world-class iron ore assets, expanding copper production and strong cash distributions, but commodity cyclicality, heavy project spending and a historically elevated valuation constrain near-term upside.

Score
69
Travere Therapeutics, Inc.
TVTX·Healthcare
B ★★★Hold
Current$52.42
Target$64.56
Return+23.2%
Nov 5, 2026

Travere Therapeutics can create substantial value through FILSPARI's expanding IgAN and FSGS franchise, but concentrated product exposure, uneven profitability, and demanding commercial expectations limit the margin of safety.

Score
69
California Resources Corporation
CRC·Energy
B ★★★Hold
Current$50.45
Target$59.11
Return+17.2%
Nov 5, 2026

California Resources offers resilient California oil production cash flow, shareholder distributions, and infrastructure optimization potential, but commodity volatility and state-specific regulatory constraints limit long-term predictability.

Score
69
Sabra Health Care REIT, Inc.
SBRA·Real Estate
B ★★★Hold
Current$21.09
Target$22.47
Return+6.5%
Nov 5, 2026

Sabra offers attractive dividend income and growing senior housing cash flows supported by demographic demand, but historical valuation premiums, operator credit exposure, and equity dilution limit its near-term upside.

Score
69
Grifols, S.A.
GRFS·Healthcare
B ★★★Hold
Current$8.60
Target$10.50
Return+22.1%
Nov 5, 2026

Grifols combines durable plasma-derived medicine demand with improving cash flow and deleveraging potential, but substantial debt, capital intensity, and Chinese albumin weakness constrain its valuation recovery.

Score
69
Transocean Ltd.
RIG·Energy
B ★★★Hold
Current$5.45
Target$5.67
Return+4.0%
Nov 5, 2026

Transocean offers a leveraged offshore drilling recovery opportunity backed by substantial backlog and improving cash flow, but cyclical demand, remaining debt, and Valaris merger dilution threaten per-share returns.

Score
69